ClinicalTrials.gg

Program

SL1002

A development code. Also written as “SL-1002”.

Its studies are mostly in Osteoarthritis, Knee · Muscle Spasticity · Osteoarthritis, led by Saol Therapeutics.

Furthest: phase 3, since Nov 6, 20253 company-led studies, 3 open or runningNext primary completion: Nov 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Saol Therapeutics33 open or runningphase 3since Nov 6, 2025Mar 28, 2022Nov 30, 2026phase 3 · NCT07226258

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2022First study: phase 2 study in Muscle SpasticityFirst studyNCT05311215 · 32 enrolled · United States
  2. Jul 20, 2022Phase 2 study in OsteoarthritisNCT05470608 · 132 enrolled · United States
  3. Nov 6, 2025Phase 3 study in Osteoarthritis Knee PainNCT07226258 · 150 enrolled · United States

Ahead

  1. Nov 30, 2026Primary completion: phase 3 study in Osteoarthritis Knee PainNCT07226258

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07226258Osteoarthritis Knee Pain · United States3Active, not recruitingNov 30, 2026150
NCT05470608Osteoarthritis · United States2Active, not recruitingJan 2024132
NCT05311215Muscle Spasticity · United States2Active, not recruitingSep 202332

How it is read

Names in the registry

  • “SL-1002”, 2 entries
  • “SL1002”, 1 entry

Codes read as this program: SL1002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.